Condition: Endometrioid Cancer · Mucinous Ovarian Cancer · High Grade Serous Ovarian Cancer · Sponsor: University of Oklahoma
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
This description comes directly from the study's public registry record.
SCC IIT Office · 4052718777 · SCC-IIT-Office@ouhsc.edu
Always discuss trial participation with your own doctor first.
| AdventHealth | Orlando, Florida, United States | Recruiting |
| Louisiana State University Medical Center New Orleans | New Orleans, Louisiana, United States | Recruiting |
| University of New Mexico Comprehensive Cancer Center | Albuquerque, New Mexico, United States | Recruiting |
| Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05512208